Skip to main content

Table 2 Characteristics of patients included in the study

From: The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients

Features   Type of cancer
Total Breast Lung Colorectal Ovarian Prostate
(n = 36) (n = 16) (n = 7) (n = 6) (n = 4) (n = 3)
General       
  Age at diagnosis, median (range) in years 60 (46–86) 52 (46–66) 65 (55–74) 60 (50–86) 67 (59–79) 75 (69–75)
  Gender, n (%)       
   Male 14 (39) 0 6 (86) 4 (66) 0 3 (100)
   Female 23 (61) 16 (100) 1 (14) 2 (33) 4 (100) 0
  Early/advanced disease, n (%)       
   Early 17 (47) 10 (63) 2 (29) 2 (33) 3 (75) 0
   Advanced 19 (53) 6 (38) 5 (71) 4 (66) 1 (25) 3 (100)
  Survival, n (%)       
   Alive 29 (81) 15 (94) 7 (100) 4 (66) 1 (25) 2 (67)
   Deceased 8 (19) 1 (8) 0 2 (33) 3 (75) 1 (33)
Clinical status       
  PSa, median (range)       
   At diagnosis/prior to treatment 1 (0–3) 0 (0–2) 1 (0–3) 1 (0–3) 0 (0–1) 2 (1–3)
   During treatment 1 (0–3) 0 (0–2) 1 (0–2) 0 (0–3) 0 (0–1) 1 (1–1)
Blood counts       
  WBCb (×103/μL), median (range) 7.1 (4.0–24.9) 7.1 (5.0–12.8) 8.2 (5.2–24.9) 5.8 (4.5–6.4) 7.8 (6.1–9.5) 7.2 (4.0–8.0)
  Lymphocytes (×103/μL), median (range) 1.5 (0.0–3.6) 1.4 (0.0–2.6) 2.1 (1.0–3.1) 1.2 (0.9–1.4) 1.8 (0.5–2.4) 1.5 (1.2–1.9)
  % Lymphocytes, mean ± SEc 20.8 ±1.6 20.7 ± 3.6 24.6 ± 1.9 22.1 ± 2.2 23.2 ± 5.0 19.3 ± 3.4
Chemotherapy regime       
  Administration route, n (%)       
   Metronomic (oral) 19 (53) 5 (31) 5 (71) 6 (100) - 3 (100)
   Standard (intravenous) 17 (47) 11 (69) 2 (29) - 4 (100) -
  Drug target, n (%)       
   Anti-mitotic (alkylating agents, vinca alkaloids) 19 (53) 11 (69) 5 (72) - - 3 (100)
   Anti-DNA (alkylating agents, anti-metabolites) 12 (33) 5 (31) 1 (14) 6 (100) - -
   Anti-mitotic/Anti-DNA (taxane/anthracycline, alkylating agent/taxane, alkylating agent/anti-microtubules agent) 5 (14) - 1 (14) - 4 (100) -
  1. aPS: performance status according the ECOG/WHO scale; bWBCs: white blood cells; cSE: standard error.